Corey M Gill1, Joshua Loewenstern2, John W Rutland2, Hanane Arib3, Margaret Pain2, Melissa Umphlett4, Yayoi Kinoshita4, Russell B McBride4,5, Joshua Bederson2, Michael Donovan4, Robert Sebra3,6, Mary Fowkes4, Raj K Shrivastava2. 1. Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA. corey.gill@icahn.mssm.edu. 2. Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA. 3. Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 4. Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 5. The Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 6. Sema4, A Mount Sinai Venture, Stamford, CT, USA.
Abstract
PURPOSE: While SWI/SNF chromatin remodeling complex alterations occur in approximately 20% of cancer, the frequency and potential impact on clinical outcomes in meningiomas remains to be comprehensively elucidated. METHODS: A large series of 255 meningiomas from a single institution that was enriched for high grade and recurrent lesions was identified. We performed next-generation targeted sequencing of known meningioma driver genes, including NF2, AKT1, PIK3CA, PIK3R1, and SMO and SWI/SNF chromatin remodeling complex genes, including ARID1A, SMARCA4, and SMARCB1 in all samples. Clinical correlates focused on clinical presentation and patient outcomes are presented. RESULTS: The series included 63 grade I meningiomas and 192 high-grade meningiomas, including 173 WHO grade II and 19 WHO grade III. Samples from recurrent surgeries comprised 37.3% of the series. A total of 41.6% meningiomas were from the skull base. NF2, AKT1, PIK3CA, PIK3R1, and SMO were mutated in 40.8, 7.1, 3.5, 3.9, and 2.4% of samples, respectively. ARID1A, SMARCA4, and SMARCB1 mutations were observed in 17.3, 3.5, and 5.1% of samples, respectively. A total of 68.2% of ARID1A-mutant meningiomas harbored a p.Gln1327del in-frame deletion. ARID1A mutations were seen in 19.1% of Grade I, 16.8% of Grade II, and 15.8% of Grade III meningiomas (P = 0.9, Fisher's exact). Median overall survival was 16.3 years (95% CI 10.9, 16.8). With multivariable analysis, the presence of an ARID1A mutation was significantly associated with a 7.421-fold increased hazard of death (P = 0.04). CONCLUSION: ARID1A mutations occur with similar frequency between low and high-grade meningiomas, but ARID1A mutations are independently prognostic of worse prognosis beyond clinical and histopathologic features.
PURPOSE: While SWI/SNF chromatin remodeling complex alterations occur in approximately 20% of cancer, the frequency and potential impact on clinical outcomes in meningiomas remains to be comprehensively elucidated. METHODS: A large series of 255 meningiomas from a single institution that was enriched for high grade and recurrent lesions was identified. We performed next-generation targeted sequencing of known meningioma driver genes, including NF2, AKT1, PIK3CA, PIK3R1, and SMO and SWI/SNF chromatin remodeling complex genes, including ARID1A, SMARCA4, and SMARCB1 in all samples. Clinical correlates focused on clinical presentation and patient outcomes are presented. RESULTS: The series included 63 grade I meningiomas and 192 high-grade meningiomas, including 173 WHO grade II and 19 WHO grade III. Samples from recurrent surgeries comprised 37.3% of the series. A total of 41.6% meningiomas were from the skull base. NF2, AKT1, PIK3CA, PIK3R1, and SMO were mutated in 40.8, 7.1, 3.5, 3.9, and 2.4% of samples, respectively. ARID1A, SMARCA4, and SMARCB1 mutations were observed in 17.3, 3.5, and 5.1% of samples, respectively. A total of 68.2% of ARID1A-mutant meningiomas harbored a p.Gln1327del in-frame deletion. ARID1A mutations were seen in 19.1% of Grade I, 16.8% of Grade II, and 15.8% of Grade III meningiomas (P = 0.9, Fisher's exact). Median overall survival was 16.3 years (95% CI 10.9, 16.8). With multivariable analysis, the presence of an ARID1A mutation was significantly associated with a 7.421-fold increased hazard of death (P = 0.04). CONCLUSION:ARID1A mutations occur with similar frequency between low and high-grade meningiomas, but ARID1A mutations are independently prognostic of worse prognosis beyond clinical and histopathologic features.
Authors: Malak S Abedalthagafi; Wenya Linda Bi; Parker H Merrill; William J Gibson; Matthew F Rose; Ziming Du; Joshua M Francis; Rose Du; Ian F Dunn; Azra H Ligon; Rameen Beroukhim; Sandro Santagata Journal: Cancer Genet Date: 2015-03-18
Authors: Sameer Agnihotri; Shahrzad Jalali; Mark R Wilson; Arnavaz Danesh; Mira Li; George Klironomos; Jonathan R Krieger; Alireza Mansouri; Osaama Khan; Yasin Mamatjan; Natalie Landon-Brace; Takyee Tung; Mark Dowar; Tiantian Li; Jeffrey P Bruce; Kelly E Burrell; Peter D Tonge; Amir Alamsahebpour; Boris Krischek; Pankaj Kumar Agarwalla; Wenya Linda Bi; Ian F Dunn; Rameen Beroukhim; Michael G Fehlings; Vera Bril; Stefano M Pagnotta; Antonio Iavarone; Trevor J Pugh; Kenneth D Aldape; Gelareh Zadeh Journal: Nat Genet Date: 2016-10-10 Impact factor: 38.330
Authors: Ethan Cerami; Jianjiong Gao; Ugur Dogrusoz; Benjamin E Gross; Selcuk Onur Sumer; Bülent Arman Aksoy; Anders Jacobsen; Caitlin J Byrne; Michael L Heuer; Erik Larsson; Yevgeniy Antipin; Boris Reva; Arthur P Goldberg; Chris Sander; Nikolaus Schultz Journal: Cancer Discov Date: 2012-05 Impact factor: 39.397
Authors: Malak Abedalthagafi; Wenya Linda Bi; Ayal A Aizer; Parker H Merrill; Ryan Brewster; Pankaj K Agarwalla; Marc L Listewnik; Dora Dias-Santagata; Aaron R Thorner; Paul Van Hummelen; Priscilla K Brastianos; David A Reardon; Patrick Y Wen; Ossama Al-Mefty; Shakti H Ramkissoon; Rebecca D Folkerth; Keith L Ligon; Azra H Ligon; Brian M Alexander; Ian F Dunn; Rameen Beroukhim; Sandro Santagata Journal: Neuro Oncol Date: 2016-01-28 Impact factor: 12.300
Authors: Cristina Balbás-Martínez; María Rodríguez-Pinilla; Ariel Casanova; Orlando Domínguez; David G Pisano; Gonzalo Gómez; Josep Lloreta; José A Lorente; Núria Malats; Francisco X Real Journal: PLoS One Date: 2013-05-01 Impact factor: 3.240
Authors: Priscilla K Brastianos; Peleg M Horowitz; Sandro Santagata; Robert T Jones; Aaron McKenna; Gad Getz; Keith L Ligon; Emanuele Palescandolo; Paul Van Hummelen; Matthew D Ducar; Alina Raza; Ashwini Sunkavalli; Laura E Macconaill; Anat O Stemmer-Rachamimov; David N Louis; William C Hahn; Ian F Dunn; Rameen Beroukhim Journal: Nat Genet Date: 2013-01-20 Impact factor: 38.330
Authors: Stephanie M Robert; Shaurey Vetsa; Arushii Nadar; Sagar Vasandani; Mark W Youngblood; Evan Gorelick; Lan Jin; Neelan Marianayagam; E Zeynep Erson-Omay; Murat Günel; Jennifer Moliterno Journal: J Neurooncol Date: 2021-11-30 Impact factor: 4.130